Drug Trial Radar · NCT01806610
Study of Safety and Tolerability of BPS804 in Patients With Late-stage Chronic Kidney Disease
Last checked: Nov 19, 2026Latest source record: Sep 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Aug 2013
Primary completion
Apr 2014
Study completion Apr 2014
Sponsor
- Lead sponsor
- Ultragenyx Pharmaceutical IncIndustry
- Sponsor type
- Industry
- Collaborators
- Mereo BioPharma; Novartis
- First posted
- Mar 7, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the safety, tolerability, and PK following a single administration of BPS804 in patients with chronic kidney disease stage 5D (CKD-5D) on hemodialysis.
Conditions
- Chronic-kidney Disease Stage 5D on Stable Hemodialysis
Interventions
BPS804Drug
Single dose BPS804 administration.
PlaceboDrug
Single dose placebo administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of adverse events after a single administration of BPS804Time frame: 17 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.